Which pharmaceutical product category experienced the most significant direct-to-consumer telemedicine disruption between 2018-2022, leading to a major shift in traditional prescription patterns?

In recent years, the medical product landscape has been transformed by digital health platforms that bypass traditional distribution channels. These telemedicine services have created new opportunities and challenges for established pharmaceutical companies, medical device manufacturers, and healthcare providers. This poll tests your knowledge about a significant market trend that has reshaped how certain medical products reach consumers.

This is a live public trivia poll on AIPolls.Net. Vote and see real-time results.

Hair loss medications (finasteride/minoxidil)
Diabetes management medications (insulin/metformin)
Cholesterol-lowering drugs (statins)
Pain management medications (NSAIDs/opioid alternatives)